Roche's Tecentriq Wins FDA Approval In Adjuvant Lung Cancer Setting

The FDA has greenlit Roche Holdings AG's RHHBY Tecentriq and platinum-based chemotherapy as post-surgery treatment for non-small cell lung cancer with the expression of the PD-L1 biomarker covering at least 1% of tumor cells.
Related: After Bladder Cancer, Roche Pulls Breast Cancer Indication For Tecentriq In US.
The agency based its review on data from the Phase 3 IMpower010 study, which showed adjuvant Tecentriq cut the risk of relapse or death by 34% over best supportive care.
Related content: Benzinga's Full FDA Calendar.
Price Action: RHHBY shares are up 0.45% at $49.14 during the market session on the last check Monday.